Evidence map›Paper›PMID 40368934›Full record

ArticleScientific reports2025

Liposomal oncolytic adenovirus as a neoadjuvant therapy for triple-negative breast cancer.

Jaimin R Shah, Tao Dong, Abraham T Phung, Sohini Khan, Omonigho Aisagbonhi, Sarah L Blair, Michael Bouvet, William C Trogler, Andrew C Kummel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jaimin R ShahMoores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.ORCID http://orcid.org/0000-0002-8894-8853
Tao DongMoores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.ORCID http://orcid.org/0000-0002-9506-9136
Abraham T PhungMoores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.ORCID http://orcid.org/0000-0001-8146-0794
Sohini KhanMoores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.
Omonigho AisagbonhiMoores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.ORCID http://orcid.org/0000-0001-7855-8619
Sarah L BlairMoores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.
Michael BouvetMoores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.
William C TroglerDepartment of Chemistry & Biochemistry, University of California San Diego, La Jolla, CA, 92093, USA.
Andrew C KummelMoores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA. akummel@ucsd.edu.ORCID http://orcid.org/0000-0001-8301-9855

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
NCI NIH HHS P30 CA023100
6 · The paper itself

Abstract

Breast cancer remains one of the leading causes of cancer-related death, with triple-negative breast cancer (TNBC) accounting for 15-20% of cases. TNBC, characterized by the absence of ER, PR, and HER2 protein, is an aggressive form of breast cancer that is unresponsive to hormonal therapies and HER2-targeted treatments, with fewer treatment options and poorer prognosis. Oncolytic adenoviruses (Ad) are a potential treatment option for TNBC but require coxsackievirus and adenovirus receptors (CAR) to effectively enter and transduce cancer cells. This study investigates a novel neoadjuvant therapy to improve the efficacy of an oncolytic Ad with human telomerase reverse transcriptase (Ad-hTERT) in CAR-low TNBC tumors using folate surface-modified liposomes to enhance delivery. This therapy helps deescalate treatment by reducing or eliminating the need for checkpoint inhibitors or toxic chemotherapy combinations. In vitro studies using CAR-low TNBC murine 4T1-eGFP cells, CAR-high TNBC human MDA-MB-231-GFP cells and several other TNBC human cancer cell lines with varying CAR expression demonstrated significantly higher cytotoxicity with encapsulated Ad-hTERT compared to Ad-hTERT. Similar results were observed in patient-derived primary TNBC cells. In vivo studies in immunocompetent mice with CAR-low 4T1-eGFP tumors revealed that encapsulated Ad-hTERT, administered as neoadjuvant therapy, resulted in stable or reduced tumor sizes, improved survival rates, higher apoptosis of cancer cells, lower cancer cell proliferation, and increased T-cell infiltration in resected tumors. Furthermore, encapsulated Ad-hTERT prevented lung metastasis and tumor recurrence at the primary site, resulting in higher survival rates in mice. Thus, liposomal encapsulation of Ad may be a viable strategy for treating TNBC.

Indexed as

AdenoviridaeLiposomesNeoadjuvant TherapyOncolytic VirotherapyOncolytic VirusesTriple Negative Breast NeoplasmsAnimalsCell Line, TumorCoxsackie and Adenovirus Receptor-Like Membrane ProteinFemaleHumansMiceTelomeraseXenograft Model Antitumor AssaysCoxsackie and Adenovirus Receptor-Like Membrane ProteinLiposomesTelomeraseCoxsackievirus and adenovirus receptorLiposomesMetastasisNeoadjuvant therapyOncolytic adenovirusTriple-negative breast cancer

Identifiers

PMID40368934
PMCPMC12078467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.